Alexander Spira, MD, PhD | Authors

Articles

Amivantamab Plus Lazertinib Combo Shows Good Results in EGFR+ NSCLC

November 10, 2020

Alexander Spira, MD, PhD, discusses the phase 1 CHRYSALIS trial of amivantamab plus lazertinib in 2 EGFR-mutant non–small cell lung cancer patient populations, which include patients with relapsed/refractory and those who are treatment-naive.